Fellowship · Syracuse, NY
Sponsored by SUNY Upstate Medical University
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
The Lancet. Child & adolescent health · 2023 · 248 citations · Joseph Domachowske
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
The New England journal of medicine · 2022 · 477 citations · Joseph Domachowske
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
The New England journal of medicine · 2022 · 163 citations · Joseph Domachowske
Assessment of US Healthcare Personnel Attitudes Towards Coronavirus Disease 2019 (COVID-19) Vaccination in a Large University Healthcare System.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 · 157 citations · Jana Shaw
The Future of Respiratory Syncytial Virus Disease Prevention and Treatment.
Infectious diseases and therapy · 2021 · 105 citations · Joseph Domachowske
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
Nature communications · 2023 · 69 citations ·
Vaccine hesitancy in the refugee, immigrant, and migrant population in the United States: A systematic review and meta-analysis.
Human vaccines & immunotherapeutics · 2022 · 56 citations · Danielle Daniels, Jana Shaw
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
The New England journal of medicine · 2023 · 79 citations · Joseph Domachowske